Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV5-hFIX is a **gene therapy product** consisting of an adeno-associated virus serotype 5 (AAV5) vector carrying a codon-optimized gene for **human factor IX (hFIX)**, enabling expression of FIX in the liver following intravenous infusion. Designed as a one-time treatment for **hemophilia B (congenital Factor IX deficiency)**, its mechanism of action relies on delivery and subsequent expression of the hFIX gene to restore functional FIX protein levels and reduce bleeding episodes. Clinical studies show sustained increases in FIX activity and reduced bleeding rates in patients with severe or moderately severe hemophilia B. The product is a predecessor to later vectors (such as AMT-061/AAV5-hFIX-Padua and etranacogene dezaparvovec).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AAV5-hFIX.